Oncoinvent ASA announced final 24-month follow-up results from its Phase 1 clinical trial evaluating Radspherin in patients with platinum-sensitive recurrent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE